An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukaemia (ALL). Recently published clinical trial results have shown evidence that switching part of the standard chemotherapy protocol for a targeted immunotherapy, can significantly improve outcomes for young people living with the disease.

Eye experts have released new global findings that reveal how a rare eye cancer first appears, offering vital insights that will help doctors diagnose the disease earlier and improve care for patients around the world. The research draws on the International Vitreoretinal B‑Cell Lymphoma Registry, the world’s largest global project dedicated to understanding this aggressive eye cancer.

The Society of Thoracic Surgeons (STS) today elected Vinay Badhwar, MD, as its 62^nd President during the organization's Annual Meeting in New Orleans. Dr. Badhwar will guide the more than 8,000-member organization through a rapidly evolving health care landscape with a focus on technical excellence, data-driven science, and measurable impact for patients worldwide.

A research team led by Professor Fu Jin has developed an innovative method integrating Monte Carlo (MC) simulations with deep learning-based denoising technology to rapidly and accurately generate high-quality EPID transmission dose (TD) data. This breakthrough significantly enhances the efficiency of patient-specific quality assurance (PSQA), supporting the advancement of online adaptive radiation therapy (ART) in clinical practice.

This review provides a comprehensive analysis of Growth Differentiation Factor 15 (GDF15) in prostate cancer (PCa), examining its complex influence on tumor metabolism, chemoresistance, and bone metastasis. GDF15 is identified as a critical driver of PCa progression and cancer cachexia, offering diagnostic potential as a biomarker, especially when combined with PSA. The review highlights promising ongoing clinical trials involving monoclonal antibodies (e.g., AV-380, NGM120, Visugromab) that target GDF15 signaling, marking it as a significant therapeutic opportunity for novel PCa therapie